Incretins: all 1,182 studies that test it

Page 9 of 12. Open to participants first (46), then studies with results posted, then the rest; newest registration first within each.

• Effects of DPP-4 Inhibition on Calcium and Bone Metabolism in Type 2 Diabetes MellitusWithdrawnNCT02444364Early Phase 1
• Dynamic Responsiveness of Insulin Secretory Parameters To Sitagliptin and Glimeperide Administration in Type 2 DMStatus unknownNCT02443922Not applicable
• Linagliptin and Mesenchymal Stem Cells: A Pilot StudyCompletedNCT02442817Phase 4
• GLP-1 Analogs for Neuroprotection After Cardiac ArrestCompletedNCT02442791Not applicable
• Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery PatientsCompletedNCT02432976Phase 2/3
• Cognitive Dysfunction and Glucagon-like Peptide-1 AgonistsCompletedNCT02423824Phase 3
• Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon LiraglutidTerminatedNCT02417103Phase 3
• Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes SubjectsCompletedNCT02408705Phase 2
• Protective Effects of Saxagliptin (And Vitamin D3) on β Cell Function in Adult-onset Latent Autoimmune DiabetesCompletedNCT02407899Phase 4
• Sitagliptin and Endothelial DysfunctionStatus unknownNCT02406950Phase 3
• COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI TrialCompletedNCT02404376Phase 3
• The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in HumansCompletedNCT02403284Phase 4
• Effects of Linagliptin in Addition to Empagliflozin on Islet Cell PhysiologyCompletedNCT02401880Phase 4
• Study on Exploring the Effect of DPP-4 Inhibitors on β-cell Function by Using the Two-step Hyperglycemic ClampStatus unknownNCT02386943Phase 4
• Exenatide Once Weekly, Cardiovascular Risk and Type-2 DiabetesCompletedNCT02380521Phase 4
• Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and AlbuminuriaCompletedNCT02376075Phase 3
• Characterizing the Incretin Effect of Amino Acids and Defining GLP-1 Role on Skeletal MuscleCompletedNCT02370745Not applicable
• The Lira Pump TrialCompletedNCT02351232Phase 2/3
• Autoinjector Device Assessment StudyCompletedNCT02349802Phase 1
• Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP)CompletedNCT02347501Phase 2
• Efficacy and Mechanism of Exenatide on Improving Heart Function in Type 2 Diabetes With Heart Failure PatientsStatus unknownNCT02344641Not applicable
• Effects of Liraglutide on ER Stress in Obese Patients With Type 2 DiabetesStatus unknownNCT02344186Phase 4
• Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination TherapyCompletedNCT02338921Phase 4
• Influence of Gut Hormones on Food Intake After Roux-en-Y Gastric Bypass SurgeryCompletedNCT02336659Not applicable
• Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes TrialCompletedNCT02330406Phase 4
• A Comparison of Exenatide and Insulin GlargineCompletedNCT02325960Phase 4
• Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal SubjectsCompletedNCT02320045Phase 1
• Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 DiabetesCompletedNCT02315495Phase 3
• Liraglutide to Improve corONary Haemodynamics During Exercise streSSCompletedNCT02315001Phase 2
• Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body WeightCompletedNCT02313220Phase 2
• The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 DiabetesStatus unknownNCT02307695Phase 4
• Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell FunctionCompletedNCT02304081Phase 4
• Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 DiabetesCompletedNCT02303730Phase 4
• Effects of Sitaglpitin on Endothelial Function During the OGTT in T2DMStatus unknownNCT02301806Phase 4
• Sitagliptin and Brown Adipose TissueCompletedNCT02294084Phase 4
• Trial for People With Established Type 2 Diabetes During RamadanCompletedNCT02292290Phase 4
• Effects of Saxagliptin on Adipose Tissue Inflammation in HumansCompletedNCT02285985Phase 4
• The Effect of Liraglutide in Patients With Prediabetes and Kidney FailureWithdrawnNCT02284230Phase 2
• Efficacy and Safety of Saxagliptin VS. Glimepiride in Chinese T2DM Patients Controlled Inadequately With MetforminCompletedNCT02280486Phase 4
• Effect of Linagliptin on TRL MetabolismStatus unknownNCT02280174Phase 4
• Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRIWithdrawnNCT02263677Phase 4
• Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical UnitWithdrawnNCT02250794Phase 4
• DPP-IV Inhibition Prior to Development of Diabetes in Patients With Cystic FibrosisStatus unknownNCT02239458Not applicable
• Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male SubjectsCompletedNCT02235961Phase 1
• Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid SecretionTerminatedNCT02231658Phase 1
• The Practical Evidence of Antidiabetic Combination Therapy in KoreaCompletedNCT02231021Phase 4
• Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy VolunteersCompletedNCT02221414Phase 1
• Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy VolunteersCompletedNCT02221401Phase 1
• Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy VolunteersCompletedNCT02220647Phase 1
• the Pharmacokinetic Profiles of Linagliptin With DW1029MCompletedNCT02212782Phase 1
• Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectorsCompletedNCT02207348Phase 1
• Liraglutide Actions on the Liver: Effects on Glucose PhosphorylationWithdrawnNCT02198209Phase 4
• Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)CompletedNCT02194595Phase 3
• Correlation Between Plasma- and Endothelial DPP-4 ActivityCompletedNCT02192853Phase 4
• PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary SyndromeCompletedNCT02187250Phase 4
• The Effect of Multiple Oral Doses of BI 1356 BS on Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of Simvastatin and on the Pharmacokinetics of Its Metabolite Simvastatin Acid in Healthy Male VolunteersCompletedNCT02183623Phase 1
• Study to Evaluate the Effect of Multiple Doses of Rifampicin on the Multiple-dose Pharmacokinetics of Linagliptin in Healthy VolunteersCompletedNCT02183584Phase 1
• Pharmacokinetics of Single and Multiple Oral Doses of BI 1356 in Healthy Chinese VolunteersCompletedNCT02183532Phase 1
• Bioavailability of BI 1356 BS and Metformin After Co-administration Compared to the Bioavailability of BI 1356 BS Alone and Metformin Alone in Healthy Male VolunteersCompletedNCT02183506Phase 1
• Bioavailability of BI 1356 Administered With and Without Food to Healthy Male and Female SubjectsCompletedNCT02183493Phase 1
• Effect of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male SubjectsCompletedNCT02183467Phase 1
• Bioavailability of BI 1356 and Glyburide in Healthy Male and Female VolunteersCompletedNCT02183428Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 DiabetesCompletedNCT02183415Phase 1
• Pharmacokinetics, Safety and Tolerability of Digoxin With or Without Co-administration of BI 1356 in Healthy VolunteersCompletedNCT02183402Phase 1
• Bioavailability of Warfarin After Coadministration With Multiple Doses of BI 1356 Compared to the Bioavailability of Warfarin Alone in Healthy Male VolunteersCompletedNCT02183389Phase 1
• Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy SubjectsCompletedNCT02183376Phase 1
• Bioavailability of BI 1356 After Single Oral Administration Given as Different Tablet Formulation in Healthy Male VolunteersCompletedNCT02183363Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 DiabetesCompletedNCT02183350Phase 1
• Bioavailability of BI 1356 With and Without Co-administration of Pioglitazone and the Bioavailability of Pioglitazone With and Without Coadministration of BI 1356 in Healthy Male and Female VolunteersCompletedNCT02183337Phase 1
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male VolunteersCompletedNCT02183311Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male VolunteersCompletedNCT02183298Phase 1
• Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BSCompletedNCT02180503Phase 1
• Effect of Multiple BI 1356 Doses of on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Female Premenopausal SubjectsCompletedNCT02175394Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male SubjectsCompletedNCT02173665Phase 1
• Pharmacokinetics and Pharmacodynamics of Multiple 5 mg Doses of BI 1356 p.o. Given Once Daily Compared to Multiple 2.5 mg Doses Given Twice Daily in Healthy Male and Female VolunteersCompletedNCT02173652Phase 1
• Bioavailability of Combination Tablet BI 1356/Metformin Compared With Single BI 1356 and Metformin Administered Together to Healthy Male and Female SubjectsCompletedNCT02173639Phase 1
• Relative Bioavailability of BI 10773 and Linagliptin in Healthy Male VolunteersCompletedNCT02172222Phase 1
• Bioavailability of BI 10773 and Sitagliptin in Healthy Male VolunteersCompletedNCT02172196Phase 1
• GLP-1 Agonism Stimulates Browning of Subcutaneous White Adipose Tissue in Obesity MenCompletedNCT02170324Phase 4
• Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes MellitusStatus unknownNCT02162550Phase 4
• Cystic Fibrosis Related DiabetesStatus unknownNCT02148978Not applicable
• Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults With PrediabetesCompletedNCT02140983Phase 1
• Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential TherapyStatus unknownNCT02129985Phase 4
• The Effect of Glucagon-Like Peptide-1 (GLP-1) on Pulmonary Vascular Resistance (PVR) in Patients With Heart FailureCompletedNCT02129179Phase 1
• GLP-1 Loading During Elective Percutaneous Coronary InterventionStatus unknownNCT02127996Phase 2
• Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory StatusStatus unknownNCT02118376Not applicable
• Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin InjectionsCompletedNCT02113332Phase 2
• Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.WithdrawnNCT02109315Phase 1
• Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 DiabetesCompletedNCT02106104Phase 4
• Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes MellitusStatus unknownNCT02097342Phase 4
• Liraglutide as add-on to Insulin in Type 1 DiabetesCompletedNCT02092896Phase 3
• Safety Evaluation of Adverse Reactions in DiabetesCompletedNCT02092597Phase 4
• DPP-4 Inhibition, Incretins and Islet FunctionCompletedNCT02089438Phase 4
• Effect of Repeated Administration of Liraglutide on Insulinogenic IndicesCompletedNCT02089256Phase 4
• Exenatide and Weight Loss for Diabetes PreventionCompletedNCT02084654Phase 1
• GLP-1 Response and Effect in Individuals With Obesity Causing Genetic MutationsCompletedNCT02082496Phase 2
• Effect of Linagliptin on Vascular Inflammation in Patients With Type 2 Diabetes MellitusTerminatedNCT02077309Phase 3
• Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)CompletedNCT02060201Phase 1
• A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes MellitusStatus unknownNCT02059564Phase 1
• Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)Status unknownNCT02055014Phase 4

← Incretins overview